Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 11

Recurrent candidal intertrigo: challenges and solutions

Authors Metin A, Dilek N, Bilgili SG

Received 28 August 2017

Accepted for publication 10 January 2018

Published 17 April 2018 Volume 2018:11 Pages 175—185

DOI https://doi.org/10.2147/CCID.S127841

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg


Ahmet Metin,1 Nursel Dilek,2 Serap Gunes Bilgili3

1Department of Dermatology and Venereology, Medical School of Ankara, Yildirim Beyazit University, Ankara, Turkey; 2Department of Dermatology and Venereology, Medical School of Recep, Tayyip Erdoğan University, Rize, Turkey; 3Department of Dermatology and Venereology, Medical School of Yuzuncu, Yil University, Van, Turkey

Abstract: Intertrigo is a common inflammatory dermatosis of opposing skin surfaces that can be caused by a variety of infectious agents, most notably candida, under the effect of mechanical and environmental factors. Symptoms such as pain and itching significantly decrease quality of life, leading to high morbidity. A multitude of predisposing factors, particularly obesity, diabetes mellitus, and immunosuppressive conditions facilitate both the occurrence and recurrence of the disease. The diagnosis of candidal intertrigo is usually based on clinical appearance. However, a range of laboratory studies from simple tests to advanced methods can be carried out to confirm the diagnosis. Such tests are especially useful in treatment-resistant or recurrent cases for establishing a differential diagnosis. The first and key step of management is identification and correction of predisposing factors. Patients should be encouraged to lose weight, followed up properly after endocrinologic treatment and intestinal colonization or peri-orificial infections should be medically managed, especially in recurrent and resistant cases. Medical treatment of candidal intertrigo usually requires topical administration of nystatin and azole group antifungals. In this context, it is also possible to use magistral remedies safely and effectively. In case of predisposing immunosuppressive conditions or generalized infections, novel systemic agents with higher potency may be required.

Keywords: Candida, intertrigo, recurrent candidal intertrigo, candidiasis, candidosis, candidal predisposals

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]